Eiger BioPharmaceuticals (EIGR) Reports In-Line Q4 EPS

Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q4 EPS of ($0.64), in-line with the analyst estimate of ($0.64). Revenue for the quarter came in at $3.36 million versus the consensus estimate of $3.34 million.

For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c